PCM
LXRX icon

Portolan Capital Management’s Lexicon Pharmaceuticals LXRX Stock Holding History

Portolan Capital Management’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-471,015
Closed -$1.96M – 128
2019
Q4 		$1.96M Buy
+471,015
New +$1.81M 0.2% 86

Other funds holding LXRX

AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
UL
Ulys LLC New York $25.4M AUM 201.03% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
PAMU
Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

Portolan Capital Management's LXRX Position: Q1 2020 in Review

Portolan Capital Management sold out of Lexicon Pharmaceuticals (LXRX) in Q1 2020, closing a stake of 471,015 shares — an estimated $1.96M sold.

Portolan Capital Management first reported a position in LXRX in Q4 2019 and held it in 1 quarter. The position peaked at $1.96M in Q4 2019. 113 funds tracked by Wall St. Rank hold LXRX as of Q1 2020.

  • Portolan Capital Management reported no remaining Lexicon Pharmaceuticals position as of Q1 2020 after selling out during the quarter.
  • Portolan Capital Management sold 471,015 Lexicon Pharmaceuticals shares in Q1 2020, an estimated $1.96M.
  • Portolan Capital Management first reported a position in Lexicon Pharmaceuticals in Q4 2019 and held it in 1 quarter.
  • Portolan Capital Management's Lexicon Pharmaceuticals position peaked at $1.96M in Q4 2019.
  • 113 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2020.

Based on Portolan Capital Management's 13F filing for Q1 2020, filed 14 May 2020.